Investigation of the prognostic value of CD4 T cell subsets expanded from tumor-infiltrating lymphocytes of colorectal cancer liver metastases.
CD4-positive t-lymphocytes
adaptive immunity
biomarkers
gastrointestinal neoplasms
lymphocytes
tumor
tumor-infiltrating
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
accepted:
16
10
2020
entrez:
24
11
2020
pubmed:
25
11
2020
medline:
18
9
2021
Statut:
ppublish
Résumé
The positive role of CD8+ tumor-infiltrating lymphocytes (TIL) in patients with colorectal cancer (CRC) has been well described but the prognostic value of CD4 T cell subsets remained to be investigated. In this study, we expanded TIL from surgically resected liver metastases of patients with CRC and characterized the phenotype and the prognostic value of expanded-CD4 T cells. Liver metastases were surgically resected from 23 patients with CRC. Tumors were enzymatically digested and cultured in high dose of interleukin-2 for up to 5 weeks. T cell phenotype and reactivity of cultured-T cells were measured by flow cytometry and correlated with patients' clinical outcomes. We successfully expanded 21 over 23 TIL from liver metastases of patients with CRC. Interestingly, we distinguished two subsets of expanded T cells based on T cell immunoglobulin mucin domain-containing protein 3 (TIM-3) expression. Medians fold expansion of expanded T cells after rapid expansion protocol was higher in CD3 Our data confirmed the presence of Th17 cells in expanded T cells from liver metastases. Among CD4 T cell characteristics investigated, TIM-3 but not programmed cell death protein 1 predicted the expansion capacity of TIL while only the Th17 phenotype showed correlation with patients' survival, suggesting a particular role of this T cell subset in CRC immune contexture. NCT02817178.
Sections du résumé
BACKGROUND
The positive role of CD8+ tumor-infiltrating lymphocytes (TIL) in patients with colorectal cancer (CRC) has been well described but the prognostic value of CD4 T cell subsets remained to be investigated. In this study, we expanded TIL from surgically resected liver metastases of patients with CRC and characterized the phenotype and the prognostic value of expanded-CD4 T cells.
METHODS
Liver metastases were surgically resected from 23 patients with CRC. Tumors were enzymatically digested and cultured in high dose of interleukin-2 for up to 5 weeks. T cell phenotype and reactivity of cultured-T cells were measured by flow cytometry and correlated with patients' clinical outcomes.
RESULTS
We successfully expanded 21 over 23 TIL from liver metastases of patients with CRC. Interestingly, we distinguished two subsets of expanded T cells based on T cell immunoglobulin mucin domain-containing protein 3 (TIM-3) expression. Medians fold expansion of expanded T cells after rapid expansion protocol was higher in CD3
CONCLUSIONS
Our data confirmed the presence of Th17 cells in expanded T cells from liver metastases. Among CD4 T cell characteristics investigated, TIM-3 but not programmed cell death protein 1 predicted the expansion capacity of TIL while only the Th17 phenotype showed correlation with patients' survival, suggesting a particular role of this T cell subset in CRC immune contexture.
TRIAL REGISTRATION NUMBER
NCT02817178.
Identifiants
pubmed: 33229508
pii: jitc-2020-001478
doi: 10.1136/jitc-2020-001478
pmc: PMC7684804
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT02817178']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Clin Cancer Res. 2014 Jan 15;20(2):331-43
pubmed: 24218514
Ann Surg Oncol. 2013 Mar;20(3):946-55
pubmed: 23010736
Science. 2015 Dec 11;350(6266):1387-90
pubmed: 26516200
Cell Immunol. 2017 Dec;322:15-25
pubmed: 29103586
Clin Cancer Res. 2010 Dec 15;16(24):6122-31
pubmed: 20668005
Euroasian J Hepatogastroenterol. 2017 Jul-Dec;7(2):166-175
pubmed: 29201802
J Immunother. 2003 Jul-Aug;26(4):332-42
pubmed: 12843795
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Cancer Immunol Immunother. 2020 Oct;69(10):1989-1999
pubmed: 32393998
Science. 2014 May 9;344(6184):641-5
pubmed: 24812403
Immunity. 2020 May 19;52(5):825-841.e8
pubmed: 32396847
Nat Med. 2016 Jun;22(6):679-84
pubmed: 27111280
Nat Rev Immunol. 2018 Oct;18(10):635-647
pubmed: 30057419
Int J Mol Sci. 2020 Feb 29;21(5):
pubmed: 32121394
Clin Dev Immunol. 2013;2013:436307
pubmed: 24382972
Immunity. 2017 Nov 21;47(5):848-861.e5
pubmed: 29126798
Nat Immunol. 2011 Jun;12(6):492-9
pubmed: 21739672
Cancer Immunol Immunother. 2018 Aug;67(8):1221-1230
pubmed: 29845338
Science. 2015 Jan 23;347(6220):400-6
pubmed: 25477212
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Nat Med. 2019 Jan;25(1):89-94
pubmed: 30510250
Blood. 2009 Aug 6;114(6):1141-9
pubmed: 19470694
J Immunother. 2008 Oct;31(8):742-51
pubmed: 18779745
Cell. 2015 Dec 3;163(6):1400-12
pubmed: 26607794
N Engl J Med. 2016 Dec 8;375(23):2255-2262
pubmed: 27959684
J Clin Oncol. 2011 Feb 20;29(6):610-8
pubmed: 21245428
Cancer Res. 2015 Sep 15;75(18):3747-59
pubmed: 26183926
Am J Pathol. 2013 Jan;182(1):10-20
pubmed: 23159950
Nat Med. 2013 Jun;19(6):747-52
pubmed: 23644516
Immunity. 2016 Mar 15;44(3):698-711
pubmed: 26982367
Immunity. 2019 Jul 16;51(1):77-89.e6
pubmed: 31229354
Lancet Oncol. 2018 Jun;19(6):e295-e304
pubmed: 29893261
N Engl J Med. 2005 Dec 22;353(25):2654-66
pubmed: 16371631
PLoS One. 2013 Sep 30;8(9):e76186
pubmed: 24098777
Cancer Res. 2016 Sep 15;76(18):5241-52
pubmed: 27496709
J Immunol. 2013 Sep 1;191(5):2217-25
pubmed: 23904171
Cancer Res. 2011 Feb 15;71(4):1263-71
pubmed: 21303976
J Clin Oncol. 2016 Jul 10;34(20):2389-97
pubmed: 27217459
Clin Cancer Res. 2011 Jul 1;17(13):4550-7
pubmed: 21498393
J Immunol. 2010 Jan 1;184(1):452-65
pubmed: 19949105
Nat Rev Immunol. 2019 Nov;19(11):665-674
pubmed: 31570879
Nat Med. 2015 Jan;21(1):81-5
pubmed: 25531942
J Clin Invest. 2016 Jan;126(1):318-34
pubmed: 26657860
Clin Cancer Res. 2019 Mar 1;25(5):1486-1493
pubmed: 30518633
Ann Surg Oncol. 2009 Sep;16(9):2524-30
pubmed: 19568816
Science. 2018 Nov 23;362(6417):952-956
pubmed: 30361387
Curr Opin Immunol. 2009 Apr;21(2):200-8
pubmed: 19285848
Immunity. 2019 Feb 19;50(2):302-316
pubmed: 30784578
Gut. 2015 Oct;64(10):1593-604
pubmed: 25608525
Ann Surg Oncol. 2017 Jul;24(7):1835-1842
pubmed: 28213791
Nat Med. 2013 Sep;19(9):1114-23
pubmed: 23913124